Osimertinib (Tagrisso) is available on the NHS for treating locally advanced or metastatic, epidermal growth factor receptor (EGFR) mutation-positive, non-small-cell lung cancer (NSCLC) in adults who have not had treatment for NSCLC before.
Information and support
The NHS website may be a good place to find out more.
These organisations can give you advice and support:
- British Lung Foundation, 03000 030 555
- Roy Castle Lung Cancer Foundation, 0333 323 7200
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
This page was last updated: 14 October 2020